Status:
WITHDRAWN
Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This pilot research trial studies molecular signatures of the return of cancer after a period of improvement (relapse) in tissue samples from patients with small cell lung cancer who are receiving or ...
Detailed Description
PRIMARY OBJECTIVES: I. To collect and analyze small cell lung cancer (SCLC) tumor DNA and ribonucleic acid (RNA) from 3 human patients before and after relapse to identify the molecular signatures of...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Any patient seen at Norris or County with histologically confirmed SCLC, with tissue in the Norris Cancer Center Tumor Repository
- Patients must be undergoing or about to start first line treatment with cisplatin and etoposide
- Patients may not have a second malignancy
Exclusion
Key Trial Info
Start Date :
August 22 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 22 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02250404
Start Date
August 22 2014
End Date
August 22 2019
Last Update
May 25 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles County-USC Medical Center
Los Angeles, California, United States, 90033
2
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033